ELDN Eledon Pharmaceuticals, Inc.

NASDAQ
$3.54

Eledon Pharmaceuticals, Inc. (ELDN) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.7% since its last earnings release on August 13, 2026.

Eledon Pharmaceuticals Reported In-line with Estimates
Thursday, August 13, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.20)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.54

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow